Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a kind of curcumin derivative in the preparation of anti-diabetes and its complication medicine

A technology of curcumin derivatives and diabetes, which is applied in the fields of application, food preparation, drug combination, etc., can solve the problems that have not been reported in the literature, and achieve the effect of improving glucose tolerance, good expected effect, reducing fasting blood sugar and glycosylated hemoglobin

Active Publication Date: 2011-12-28
FUJIAN MEDICAL UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Majeed et al disclosed the patent (U.S.Patent, US 7,521,580) that this compound is used for the treatment of cystic fibrosis, but (1E, 6E)-1,7-bis(3,5-di-tert-butyl-4-hydroxyphenyl ) Whether hepta-1,6-diene-3,5-dione has the effect of preventing and treating diabetes and its complications has not been reported in the literature so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a kind of curcumin derivative in the preparation of anti-diabetes and its complication medicine
  • Application of a kind of curcumin derivative in the preparation of anti-diabetes and its complication medicine
  • Application of a kind of curcumin derivative in the preparation of anti-diabetes and its complication medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Curcumin derivatives (1E, 6E)-1,7-bis(3,5-di-tert-butyl-4-hydroxyphenyl)hepta-1,6-diene-3,5-dione (hereinafter referred to as L3 ) on glucose and lipid metabolism in hyperlipidemic diabetic mice

[0035] 1.1 Establishment of hyperlipidemia and diabetes mouse model

[0036] After all the mice were adaptively fed for one week, 18 mice were randomly selected as the normal control group, and the rest were modeled. The day before modeling, all mice were fasted overnight, and streptozotocin was dissolved in 0.1mol / L citric acid-sodium citrate buffer (pH 4.2) to make a solution with a concentration of 0.5% by weight. The model group and each The treatment group was injected intraperitoneally with 50 mg / kg body weight, once every other day for a total of 5 times, and the mice in the normal control group were injected intraperitoneally with the same volume of citric acid-sodium citrate buffer. After 5 injections, at intervals of one week, fasting overnight, tail cutting blood ...

Embodiment 2

[0059] Curcumin derivatives (1E, 6E)-1,7-bis(3,5-di-tert-butyl-4-hydroxyphenyl)hepta-1,6-diene-3,5-dione (L3) to Effects of Vital Organ Complications in Hyperlipidemic Diabetic Mice

[0060] 2.1 Establishment of hyperlipidemia and diabetes mouse model

[0061] Same as 1.1 method.

[0062] 2.2 Drug intervention and index detection

[0063] Animal grouping and administration are the same as 1.1. The mice were sacrificed at 4 weeks and 16 weeks after administration, and the pancreas, liver, bilateral kidneys, heart, thoracic aorta, and abdominal aorta were separated, rinsed with cold saline, blotted dry with filter paper, weighed the liver, and both kidneys, respectively. Calculate body mass index. The thoracic aorta and abdominal aorta were fixed with 4% paraformaldehyde solution by weight, and the liver and kidney were fixed with 10% neutral formaldehyde solution by weight. The liver and aorta were embedded in paraffin, sectioned, and routinely stained with HE.

[0064] 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a curcumin derivative to preparation of medicines for resisting diabetes and complication thereof and in particular relates to application of (1E,6E)-1,7-di(3,5-ditertbutyl-4-hydroxyl phenyl)heptyl-1,6-diene-3,5-diketone to preparation of medicines, health-care products and food for preventing and treating diabetes and complication thereof. The (1E,6E)-1,7-di(3,5-ditertbutyl-4-hydroxyl phenyl)heptyl-1,6-diene-3,5-diketone can obviously reduce serum, liver triglyceride, total cholesterol and low-density lipoprotein of high fat feed and streptozotocin induced diabetes model mice, can reduce fasting blood glucose and glycated hemoglobin of the model mice, can improve glucose tolerance of the model mice, can obviously improve glycometabolism and lipid metabolism of the diabetes model mice, and can obviously reduce fatty degeneration of liver and aortic arch and lesion of atherosclerosis.

Description

technical field [0001] The present invention relates to a curcumin derivative (1E, 6E)-1,7-bis(3,5-di-tert-butyl-4-hydroxyphenyl)hepta-1,6-diene-3,5-di The application of ketone in the preparation of medicines and health products for preventing and treating diabetes and its complications. Background technique [0002] Diabetes is the third leading cause of human death. At present, there are more than 200 million patients worldwide, and nearly 20 million patients in my country. In recent years, the incidence of diabetes has increased year by year, seriously affecting people's lives and even threatening their lives, and bringing heavy economic burdens to society and individuals. It has become an increasingly serious public health problem in all countries in the world. [0003] Diabetes causes protracted high blood sugar, causing sugar, fat, protein, and secondary vitamin, water, and electrolyte metabolic disorders, often accompanied by atherosclerosis, microvascular disease, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/12A61P3/10A61P3/06A61P9/10A61P1/16A23L1/29A23L1/30A23L33/00
Inventor 许建华郑斌刘洋温彩霞
Owner FUJIAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com